Helius Medical Updates Share Count and Capital Structure

Helius Medical Technologies ( (HSDT) ) has shared an announcement.

Solana Company announced that, as of February 20, 2026, it has 52,802,604 shares of common stock issued and outstanding, along with pre-funded warrants covering an additional 23,930,181 shares. The disclosure clarifies the company’s current equity and potential dilution profile, providing investors and other stakeholders with an updated view of its capital structure at that date.

The most recent analyst rating on (HSDT) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Spark’s Take on HSDT Stock

According to Spark, TipRanks’ AI Analyst, HSDT is a Neutral.

The score is pressured primarily by weak financial performance (large ongoing losses, persistent cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). Earnings-call positives (significant fundraising and favorable PoNS study outcomes) provide some offset, but the magnitude of losses and higher expenses limit the overall rating; valuation offers limited support due to negative earnings and no stated dividend yield.

To see Spark’s full report on HSDT stock, click here.

More about Helius Medical Technologies

Solana Company, formerly known as Helius Medical Technologies, Inc., is a publicly traded firm with its capital structure comprising common stock and pre-funded warrants. The change in corporate name suggests an evolution in the company’s branding while retaining its existing share and warrant framework as part of its financing structure.

Average Trading Volume: 531,641

Technical Sentiment Signal: Strong Sell

Current Market Cap: $82.6M

See more insights into HSDT stock on TipRanks’ Stock Analysis page.